Lupin Ltd., Biocon Ltd., Granules India Ltd., shares gained despite the sentiment for overall pharmaceutical stocks got affected after US President Donald Trump threatened to impose steep tariffs on ...

Lupin shares were trading at Rs 1,965 on the NSE, a rise of over 2% from the previous close. The stock is among the top gainers on the Nifty Midcap 150 index.

Desco Infratech Ltd has received a lowest bid confirmation at the L1 Stage, Part-1 being declared as the Successful Bidder for the Works of Laying of PE Network and Associated Works in the CGD Project ...

Lupin Limited announced that it has secured the United States Food and Drug Administration (USFDA)’s approval for its abbreviated new drug application (ANDA). The approval is received for ...

Indian drugmaker Lupin Ltd. has announced that it spinned off its consumer healthcare business with effect from July 1. The newly formed wholly owned subsidiary will be called as LupinLife Consumer ...

Shree Sales Corporation Canon Service Center in Aurangabad, Maharashtra - Shree Sales Corporation is an authorised service center of Canon in Aurangabad. Find Shree Sales Corporation address, contact ...

Vivek Infotech Canon Service Center in Aurangabad, Maharashtra - Vivek Infotech is an authorised service center of Canon in Aurangabad. Find Vivek Infotech address, contact number, email, user reviews ...

Lupin has launched Prucalopride tablets in the US following USFDA approval. The bowel disorder treatment enters a $184 million market and will be manufactured at the company's Goa facility.

Lupin launches generic Prucalopride tablets for chronic idiopathic constipation in the US market, a bioequivalent to Takeda's Motegrity, with estimated annual sales of USD 184 million.

Lupin gets USFDA nod for new constipation drug, stock gains This product, bioequivalent to Motegrity Tablets of Takeda Pharmaceuticals, will be manufactured at Lupin's Goa facility in India.

Lupin announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its abbreviated new drug application (ANDA) for Prucalopride tablets.